Format

Send to

Choose Destination
J Clin Endocrinol Metab. 2018 Feb 1;103(2):532-538. doi: 10.1210/jc.2017-01927.

Breast Development in Transwomen After 1 Year of Cross-Sex Hormone Therapy: Results of a Prospective Multicenter Study.

Author information

1
Department of Endocrinology and Center of Expertise on Gender Dysphoria, VU University Medical Center, Amsterdam, The Netherlands.
2
Department of Clinical Chemistry, Endocrine Laboratory, VU University Medical Center, Amsterdam, The Netherlands.
3
Laboratory of Endocrinology, Academic Medical Center, Amsterdam, The Netherlands.
4
Sexual Medicine and Andrology Unit, Department of Experimental, Clinical, and Biomedical Sciences, University of Florence, Florence, Italy.
5
Department of Endocrinology, Oslo University Hospital, Oslo, Norway.
6
Department of Endocrinology and Center for Sexology and Gender, Ghent University Hospital, Ghent, Belgium.

Abstract

Context:

Breast development is a key feature of feminization and therefore important to transwomen (male-to-female transgender persons). It is not exactly known when breast development starts after initiating cross-sex hormone therapy (CHT) and how much growth may be expected.

Objective:

To investigate breast development in transwomen during their first year of CHT and whether clinical or laboratory parameters predict breast development.

Design:

This study was performed as part of the European Network for the Investigation of Gender Incongruence, which is a prospective multicenter cohort study.

Setting:

Gender clinics in Amsterdam, Ghent, and Florence.

Participants:

Transwomen who completed the first year of CHT (n = 229).

Intervention:

CHT.

Main Outcome Measures:

Breast development in centimeter and cup size.

Results:

The median age of the included transwomen was 28 years (range, 18 to 69). Mean breast-chest difference increased to 7.9 ± 3.1 cm after 1 year of CHT, mainly resulting in less than an AAA cup size (48.7%). Main breast development occurred in the first 6 months of therapy. Serum estradiol levels did not predict breast development after 1 year of CHT (first quartile, 3.6 cm [95% confidence interval (CI), 2.7 to 4.5], second quartile, 3.2 cm [95% CI, 2.3 to 4.2], third quartile, 4.4 cm [95% CI, 3.5 to 5.3], and fourth quartile, 3.6 cm [95% CI, 2.7 to 4.5]).

Conclusion:

This study shows that, after 1 year of CHT, breast development is modest and occurs primarily in the first 6 months. No clinical or laboratory parameters were found that predict breast development.

PMID:
29165635
DOI:
10.1210/jc.2017-01927
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center